Clinical Trial Update: Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating induction chemotherapy with carboplatin/paclitaxel followed by concurrent chemoradiation including ZD1839 (Iressa), 5-FU, hydroxyurea, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• 5-FU (5-fluorouracil)
• CARBOPLATIN (Carboplatin)
• HYDROXYUREA (Hydroxyurea)
• PACLITAXEL (PACLITAXEL)
• ZD1839 (Iressa) (gefitinib)

Snippet

Sponsor: University of Chicago | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-06-02